
Mycobacterium abscessus-pulmonary disease (MABS-PD) is challenging to treat due to its resistance to antibiotics. We identified 82 treatment-naïve MABS-PD patients from a prospective observational cohort who were treated with regimens containing inhaled amikacin with or without clofazimine between March 2015 and June 2018. During the initial phase...
Like
Save
Share